Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Nov;30(11):1555-61.
doi: 10.1093/sleep/30.11.1555.

Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia

Thomas Roth  1 , Roberta Rogowski, Steven Hull, Howard Schwartz, Gail Koshorek, Bruce Corser, David Seiden, Alan Lankford
Affiliations
Randomized Controlled Trial

Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia

Thomas Roth et al. Sleep. 2007 Nov.

Abstract

Study objectives: To evaluate the efficacy and safety of doxepin 1, 3, and 6 mg in insomnia patients.

Design: Adults (18-64 y) with chronic primary insomnia (DSM-IV) were randomly assigned to one of four sequences of 1 mg, 3 mg, and 6 mg of doxepin, and placebo in a crossover study. Treatment periods consisted of 2 polysomnographic assessment nights with a 5-day or 12-day drug-free interval between periods. Efficacy was assessed using polysomnography (PSG) and patient-reported measures. Safety analyses included measures of residual sedation and adverse events.

Measurements and results: Sixty-seven patients were randomized. Wake time during sleep, the a priori defined primary endpoint, was statistically significantly improved at the doxepin 3 mg and 6 mg doses versus placebo. All three doses had statistically significant improvements versus placebo for PSG-defined wake after sleep onset, total sleep time, and overall sleep efficiency (SE). SE in the final third-of-the-night also demonstrated statistically significant improvement at all doses. The doxepin 6 mg dose significantly reduced subjective latency to sleep onset. All three doxepin doses had a safety profile comparable to placebo. There were no statistically significant differences in next-day residual sedation, and sleep architecture was generally clinically preserved.

Conclusions: In adults with primary insomnia, doxepin 1 mg, 3 mg, and 6 mg was well-tolerated and produced improvement in objective and subjective sleep maintenance and duration endpoints that persisted into the final hour of the night. The side-effect profile was comparable to placebo, with no reported anticholinergic effects, no memory impairment, and no significant hangover/next-day residual effects. These data demonstrate that doxepin 1 mg, 3 mg, and 6 mg is efficacious in improving the sleep of patients with chronic primary insomnia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Sleep Efficiency (SE) by third-of-the-night; * denotes P <0.05; ** denotes P <0.0001.
Figure 1
Figure 1
Sleep Efficiency (SE) by hour of the night.
See this image and copyright information in PMC

References

    1. Breslau N, Roth T, Rosenthal L, et al. Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young adults. Biol Psychiatry. 2004;39:411–8. - PubMed
    1. Ohayon MM. Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res. 1997;31:333–46. - PubMed
    1. Lichstein KL, Durrence HH, Taylor DJ, et al. Epidemiology of sleep: age, gender, and ethnicity. Mahwah, NJ: Erlbaum; 2004.
    1. Buysse D, Reynolds CF, III, Kupfer DJ, et al. Effects of diagnosis on treatment recommendations in chronic insomnia-a report from the APA/NIMH DSM-IV field trial. Sleep. 1997;20:542–52. - PubMed
    1. Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med. 1998;158:1099–107. - PubMed

Publication types